Partner and Chairman, MD, DPhil

#fhtogglels/Read Full Bio/Close/ib

Fred Cohen is a Founder and member of the Investment Committee of Monograph, which he co-founded in 2021. Prior to Monograph, he was Co-Founder and Senior Managing Director of Vida Ventures, and Managing Partner at TPG Biotechnology, where he initiated TPG’s venture efforts in biotechnology and life sciences in 2001.

Earlier, Fred was a Professor at UCSF, where he served as Chief of the Division of Endocrinology and Metabolism and led research in prionbiology, drug design, bioinformatics, and heteropolymer chemistry. He is a member of the National Academy of Medicine, the American Academy of Arts and Sciences, and a fellow of the American College of Physicians. He has received several awards, including the Burroughs-Wellcome New Initiatives in Malaria Award, the LVMH Science Pour L’Art Prize, and the Searle Scholars Award. Fred graduated magna cum laude from Yale University in 1978, received his D.Phil. from Oxford University as a Rhodes Scholar in 1980, earned his M.D. from Stanford Medical School as an American Cancer Society Postdoctoral Fellow in 1984 and completed his internal medicine and endocrinology training at UCSF.

LinkedIn

Partner, MBA, MA

#fhtogglels/Read Full Bio/Close/ib

Charles Conn is a Partner and co-founder of Monograph, where he focuses on tech-enabled services businesses. Charles is a technology entrepreneur and was previously CEO of Oxford Sciences Innovation, a deep science venture firm, as well as founding CEO of Ticketmaster-Citysearch, where he led its IPO and acquisition of Match.com. He chairs Patagonia, and previously was CEO of the Rhodes Trust.

Charles started his career as a Partner at McKinsey & Company. He is a best-selling author on strategic problem solving, and a member of The Nature Conservancy’s European Council for Global Conservation. He graduated from Harvard Business School, Boston University, and Oxford University, where he was a Rhodes Scholar.

LinkedIn

Principal (Portfolio), BSc

#fhtogglels/Read Full Bio/Close/ib

Freddie Dear is a Principal at Monograph Capital. He was part of the founding team of portfolio company Ascend Advanced Therapies, where he held an operation role as VP, Corporate Development and remains an advisor to the company. He also sits on the board of portfolio company Nocion Therapeutics.

Prior to Monograph Capital, he was an Investment Partner at Syncona, where he was involved in a number of investments including Quell Therapeutics and Forcefield Therapeutics, where he took operational roles in founding those businesses. Prior to Syncona, he was a member of the investment team at the Wellcome Trust. Freddie holds a BSc in Biochemistry from the University of Edinburgh

LinkedIn

Principal (Portfolio), PhD, BS

#fhtogglels/Read Full Bio/Close/ib

Jaideep Dudani is a Principal at Monograph Capital and the founding CEO of Ouro Medicines, a Monograph Capital portfolio company. He currently serves on the board of Ouro Medicines and as an observer on the board of Sudo Biosciences. He was part of the founding team of Human Immunology Biosciences (HI-Bio), another Monograph Capital portfolio company, where he led portfolio development and strategy prior to the acquisition by Biogen.

Prior to Monograph Capital, he was at Relay Therapeutics, a precision medicine company focused on oncology and rare genetic diseases, where he played a cross-functional role in R&D and strategy and business development and was part of the team that took the company public. Before Relay, Jaideep was the first associate at Vida Ventures, and was involved in several of Vida’s investments, including Allogene Therapeutics (NASDAQ: ALLO), Asklepios BioPharmaceutical (which was acquired by Bayer AG in 2020), Oyster Point Pharma (acquired by Viatris), Kyverna (NASDAQ: KYTX), and Pionyr Immunotherapeutics.

Jaideep holds a PhD in Biological Engineering from MIT and a BS in Bioengineering from UCLA.

LinkedIn

Partner, DPhil, BS

#fhtogglels/Read Full Bio/Close/ib

Tim Funnell is a Partner and co-Founder at Monograph. Prior to Monograph, Tim was co-founder and Vice President of Operations for MiroBio. Tim has been an investor in the biotechnology and related life sciences industries and company-builder at Syncona, Third Rock Ventures and Oxford Sciences, gaining experience across therapeutic modalities and geographies. He began his career at the Boston Consulting Group in London. Tim trained as a pharmacologist with an undergraduate degree from University of Cambridge and DPhil from the University of Oxford.

Linkedin

Principal, PhD, MSc, BSc

#fhtogglels/Read Full Bio/Close/ib

Melisa Guven is a Principal at Monograph’s London office, where she leads investments in therapeutics and pharmaceutical services and partners closely with portfolio companies on strategy and operations. She is a board observer at Elevara Medicines, Maxion Therapeutics, and Prolynx, and has held operational roles in the former two companies. Before joining Monograph, Melisa was an Engagement Manager at L.E.K. Consulting, advising clients across the healthcare and life sciences sectors, and a fellow with the World Economic Forum’s Healthcare Industries Platform. She holds a PhD in Cancer Biology (DNA repair) from the Francis Crick Institute, an MSc in Immunology, and a BSc in Biochemistry from Imperial College London.

LinkedIn

Associate, BSc

#fhtogglels/Read Full Bio/Close/ib

Michelle He is an Associate at Monograph Capital’s San Francisco office, where she supports the firm’s investment activities across transformative life sciences companies. Prior to joining Monograph, Michelle was an Investment Manager at Tin Alley Ventures, where she evaluated early-stage opportunities and partnered with founders to help build high-growth life sciences and technology businesses.

Michelle began her career in the investment banking division at Goldman Sachs, gaining deep exposure to financial analysis, deal execution, and strategic advisory across healthcare and technology sectors. She subsequently contributed to the investment team at BGH Capital and was part of the Strategy & Operations team at FrankieOne, where she supported cross-functional initiatives to drive operational improvements.

Michelle holds a Bachelor of Science in Neuroscience from the University of Melbourne.

UK Head of Operations & Sr. EA, BA

#fhtogglels/Read Full Bio/Close/ib

Ramone is the UK Head of Operations and Senior Executive Assistant at Monograph’s London office, where he combines strategic operational oversight with high-level executive support. He brings extensive experience partnering with senior leaders, including supporting Dame Vivian Hunt at UnitedHealth Group, and previously worked as a communications specialist at McKinsey & Company with a focus on the Energy and Materials sector. At Monograph Capital, he applies his creative problem-solving skills and operational expertise to build scalable processes, enhance team effectiveness, and drive innovation across the firm. Ramone holds a BA in Theatre Arts.

LinkedIn

Partner and COO, JD, MBA, LLM

#fhtogglels/Read Full Bio/Close/ib

Mike LaGatta is a Partner and Chief Operating Officer at Monograph. Prior to joining Monograph, Mike served as the General Counsel of TPG Holdings and Chief Tax Officer of TPG. Mike brings over 20 years of investment management and transactional experience.

LinkedIn

EA & US Operations Manger, BBA

#fhtogglels/Read Full Bio/Close/ib

Kristina is an EA and Operations Manager at Monograph's San Francisco office. She has extensive experience supporting C-Suite executives in the biotech industry, including roles as executive assistant to the CEO at Walking Fish Therapeutics and senior executive assistant to the General Counsel at Frontier Medicines. Previously, she was the operations manager and executive assistant to the CEO at CODA Biotherapeutics, and supported senior executives at FivePrime Therapeutics (acquired by Amgen) and FibroGen. Kristina also has experience in commercial real estate and private equity and holds a BBA from Mount Mercy University.

Linkedin

Chief of Staff & EA, BA

#fhtogglels/Read Full Bio/Close/ib

Brandi is Chief of Staff and EA to Fred Cohen. Previously, Brandi supported several leaders at TPG, including Co-CEO Jon Winkelried, Senior Advisors Dr Fred Cohen, Edward Mower Norton Jr, and the Honorable William K. Reilly. Brandi began her career as an assistant working aboard M.Y. Silver Lining. She continued her career at the Santa Fe Film Festival, the Doha Film Institute in Qatar, and the 34th America’s Cup in San Francisco, before moving into private equity and venture capital. Brandi holds a BA in Communications from the University of Louisville.

LinkedIn

Associate, MBBS, BSc

#fhtogglels/Read Full Bio/Close/ib

Jeremias Reich is an Associate at Monograph Capital, based in the firm’s London office. He supports the investment team in sourcing and evaluating new opportunities, conducting scientific and commercial diligence, and working closely with portfolio companies.

Prior to joining Monograph, Jeremias was a Consultant in McKinsey & Company’s Life Sciences practice, advising biopharma clients on strategy, R&D, and drug development topics. Before McKinsey, he spent several years at NB Capital as a Biotech Investment Analyst and Medical Advisor, focusing on life sciences investing and translational innovation.

Jeremias trained as a physician and worked as an Academic Junior Doctor at the University of Oxford. He holds an MBBS in Medicine and a BSc in Immunity and Infection from Imperial College London.

Chief Financial Officer, MSc

#fhtogglels/Read Full Bio/Close/ib

Daniel is Chief Financial Officer of Monograph and is based in its Fort Worth offices. He leads Monograph’s financial operations, fund administration, accounting, and financial planning and reporting.

Prior to Monograph, Daniel was the Chief Financial and Operating Officer at Bios Partners, a venture capital firm specializing in life sciences, and an Associate Director at Crestline Investors. Daniel holds an MSc in Finance and a BBA in Accounting from Texas A&M University.

LinkedIn

Head of Capital Formation, BA

#fhtogglels/Read Full Bio/Close/ib

Jennifer Shah serves as the Head of Capital Formation, where she leads strategic initiatives for fundraising and investor relations. Prior to Monograph, Jennifer was the Director, Head of Product Management, Fundraising & Investor Relations at Silver Lake, where she managed capital raising efforts for their flagship fund. Before Silver Lake, she was a Director of Capital Raising at SoftBank Investment Advisers. Jennifer also worked at TPG as a Principal in the Funding Group, where she focused on their TPG Asia funds. Jennifer holds a BA in Anthropology and International Studies from Trinity College.

LinkedIn

Principal, DPhil, BS

#fhtogglels/Read Full Bio/Close/ib

Bonnie van Wilgenburg is a Principal at Monograph’s London office, where she leads investments and builds biotech companies. She is a board director at Autobahn Therapeutics and previously led due diligence on MiroBio, who were acquired by Gilead.

Before Monograph, she worked at Forbion for four years, and was a board observer at Inflazome, acquired by Roche in 2020 for US$450. Bonnie spent a decade as an academic scientist in immunology, virology, and stem cells at Oxford University and the University of Melbourne. She earned her DPhil at Oxford.

LinkedIn

Advisor (in Portfolio), MPH, BM BCh, MA

#fhtogglels/Read Full Bio/Close/ib

Charlie Zhou is an Investment Manager in Monograph’s London office, where he leads new investments and supports strategic growth of portfolio companies through both operational and director roles. Charlie is a founding member of Ouro Medicines, serves as a board director at RegASK, and a board observer at Nocion Therapeutics. Before Monograph, he was a management consultant at Bain & Company and practiced as a physician at the Royal Free London NHS Foundation Trust. Charlie completed his training at the University of Cambridge, University of Oxford, and Harvard University as a Fulbright scholar.

LinkedIn